M
Maria Grazia Bisconte
Publications - 9
Citations - 427
Maria Grazia Bisconte is an academic researcher. The author has contributed to research in topics: Deferasirox & Thalassemia. The author has an hindex of 4, co-authored 9 publications receiving 373 citations.
Papers
More filters
Journal ArticleDOI
Hepatocellular carcinoma in the thalassaemia syndromes.
Caterina Borgna-Pignatti,Gianluca Vergine,Turi Lombardo,Maria Domenica Cappellini,Paolo Cianciulli,Aurelio Maggio,Disma Renda,Maria Eliana Lai,Antonella Mandas,Gian Luca Forni,Antonio Piga,Maria Grazia Bisconte +11 more
TL;DR: Hepatocellular carcinoma (HCC) frequently complicates hepatic cirrhosis secondary to viral infection or iron overload, and patients affected by thalassaemia syndromes have a theoretically high risk of developing the tumour.
Journal ArticleDOI
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging
Alessia Pepe,Antonella Meloni,Marcello Capra,Paolo Cianciulli,Luciano Prossomariti,Cristina Malaventura,Maria Caterina Putti,A Lippi,Maria Antonietta Romeo,Maria Grazia Bisconte,Aldo Filosa,Vincenzo Caruso,Antonella Quarta,Lorella Pitrolo,Massimiliano Missere,Massimo Midiri,Giuseppe Rossi,Vincenzo Positano,Massimo Lombardi,Aurelio Maggio +19 more
TL;DR: The cohort of patients treated with oral deferiprone showed less myocardial iron burden and better global systolic ventricular function compared to the patients treatedwith oral deferasirox or subcutaneous desferrioxamine.
Journal ArticleDOI
Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: The ITHACA study
Luciana Scalone,Lorenzo G. Mantovani,Marieke Krol,Diana Rofail,S Ravera,Maria Grazia Bisconte,Caterina Borgna-Pignatti,Zelia Borsellino,Paolo Cianciulli,Domenico Pietro Paolo Gallisai,Luciano Prossomariti,Ippazio Stefàno,Maria Domenica Cappellini +12 more
TL;DR: The management of β-TM patients undergoing transfusions and ICT is efficacious, although costly, but overall benefits were not always perceived as optimal by patients, so efforts must be focused to improve patients' acceptance and satisfaction with their therapy.
Journal ArticleDOI
The Close Link of Pancreatic Iron With Glucose Metabolism and With Cardiac Complications in Thalassemia Major: A Large, Multicenter Observational Study.
Alessia Pepe,Laura Pistoia,Maria Rita Gamberini,Liana Cuccia,Angelo Peluso,Giuseppe Messina,Anna Spasiano,Massimo Allò,Maria Grazia Bisconte,Maria Caterina Putti,Tommaso Casini,Nicola Dello Iacono,Mauro Celli,Angelantonio Vitucci,Pietro Giuliano,Giuseppe Peritore,Stefania Renne,Riccardo Righi,Vincenzo Positano,Vincenzo De Sanctis,Antonella Meloni +20 more
TL;DR: Pancreatic iron is a powerful predictor not only for glucose metabolism but also for cardiac iron and complications, supporting the close link between pancreatic iron and heart disease and the need to intensify iron chelation therapy to prevent both alterations of glucose metabolism and cardiac iron accumulation.
Journal ArticleDOI
GATA1 erythroid-specific regulation of SEC23B expression and its implication in the pathogenesis of congenital dyserythropoietic anemia type II.
Roberta Russo,Immacolata Andolfo,Antonella Gambale,Gianluca De Rosa,Francesco Manna,Alessandra Arillo,Farooq Wandroo,Maria Grazia Bisconte,Achille Iolascon +8 more
TL;DR: Biallelic mutations in SEC23B gene cause congenital dyserythropoietic anemia type II (CDAII), an autosomal recessive disorder characterized by ineffective erythropOiesis, hemolytic anemia, and splenomegaly.